On June 26, ST Kangmei announced that the company will submit an application to the Shanghai Stock Exchange to withdraw other risk warnings, once successful, the company's stock abbreviation will be restored to Kangmei Pharmaceutical after five years
In 2018, it has been paying dividends for many years, and its revenue and net profit have maintained rapid growth for many years, becoming a pharmaceutical white horse stock with a market value of 100 billion
On April 30, 2019, on the grounds of accounting errors, Kangmei Pharmaceutical self-detonated 29.9 billion yuan of monetary funds were missing, and four months later, the China Securities Regulatory Commission issued an announcement to completely uncover the fact that Kangmei Pharmaceutical has been involved in financial fraud for three consecutive years and involving many subjects, with a total of more than 80 billion yuan of monetary fraud, becoming the largest fraud company in the history of A-shares
It has to be said that between stocks and stocks, it is also about fate, and some stocks are unable to express opinions because of losses of tens of millions, or annual report audits are issued unable to express opinions, and ST is implemented all the way down to delisting
Kangmei Pharmaceutical, such a major fraud, if it is placed now, it will be delisted, but a few years ago, it was only implemented to wear a hat with stars, and the rise and fall was limited to 5%, and what is even more unexpected is that it is about to apply for a hat this year
According to the data, the company will achieve an operating income of 4.874 billion yuan and a net profit of 102.5 million yuan in 2023, and an operating income of 1.201 billion yuan and a net profit of 7.471 million yuan in the first quarter of this year.